Skip to Main Content

Paper Details

De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance.
Breast
37
2017
HER, HER family members, HER family of, HER homo and heterodimers, HER receptor dimers, HER2, HER2-amplified tumors, HER2-positive breast cancer, HER2-positive tumors, PI3K, breast cancers, estrogen, estrogen receptor, patient, tumor, tumors
Author NameAffiliation
Jorge S Reis-FilhoMemorial Sloan Kettering Cancer Center
Tomás PascualHospital Clinic de Barcelona
Mothaffar F RimawiBaylor College of Medicine, USA Dan L. Duncan Comprehensive Cancer Center
Charles Kent OsborneBaylor College of Medicine, USA Dan L. Duncan Comprehensive Cancer Center
  • 1 - 4

Datasets

Release 1.2